You are here

  • Home
  • Archive
  • Volume 11, Issue 7
  • Correction: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

https://doi.org/10.1136/jitc-2022-006348corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Demerlé C, Gorvel L, Mello M, et al. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors. J Immunother Cancer 2023;11:e006348. doi: 10.1136/jitc-2022-006348

    In the original publication, Daniel Olive was not listed as a co-corresponding author. This has now been rectified.